Clinical trials: Left Sided Breast Cancer
Breast Neoplasms, Breast Cancer
Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing
Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence.
- Conditions
- Breast Neoplasms, Breast Cancer, Left Sided Breast Cancer
- Trial name
- PERSBRA (NCT04929197)
- Testing
- PERSBRA
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Medical University Hospital
Heart Failure, Breast Cancer
Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned.
- Trial name
- SCHOLAR (NCT02907021)
- Testing
- standard-of-care treatments for LV impairment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Population Health Research Institute
Breast Cancer, Right or Left Breast Mammary Reconstruction
Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer
Mammary reconstruction replaces total skin transplant, which may causing patient discomfort. It is a simple, painless and reproductible technology that avoids consequences and complications related to transplant.
- Conditions
- Breast Cancer, Right or Left Breast Mammary Reconstruction, Malignant Neoplasm Reconstruction by Tattoo of Areola of Female Breast
- Trial name
- NCT02464982
- Testing
- Tattoo
- Where
- France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Heart Failure
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned.
- Trial name
- SCHOLAR-2 (NCT04680442)
- Testing
- Trastuzumab, Pertuzumab, Trastuzumab emtansine
- Where
- 8 sites in Brazil, Canada and 1 more
- Volunteers
- 130 people
- Sponsor
- Population Health Research Institute
Port-A-Cath
Comparison of Outcomes of Right Internal Jugular Port Implantation in Patients With Right Versus Left Breast Cancer Undergoing Chemotherapy
Chemotherapy is an essential component of breast cancer treatment. Frequent intravenous injections may lead to phlebitis and limited venous access, therefore implantable venous ports are increasingly used.
- Trial name
- NCT07197320
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Golestan University of Medical sciences